UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Cell host & microbe, 2021-04, Vol.29 (4), p.529-539.e3

2021

Volltextzugriff (PDF)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

The New England journal of medicine, 2021-06, Vol.384 (24), p.2352-2354

2021

Volltextzugriff (PDF)

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

The New England journal of medicine, 2020-12, Vol.383 (24), p.2320-2332

2020

Volltextzugriff (PDF)

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Vaccine, 2020-11, Vol.38 (50), p.7892-7896

2020

Volltextzugriff (PDF)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

PLoS medicine, 2021-10, Vol.18 (10), p.e1003769-e1003769

2021

Volltextzugriff (PDF)

A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine

The New England journal of medicine, 2013-12, Vol.369 (26), p.2564-2566

2013

Volltextzugriff (PDF)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

Scientific reports, 2023-01, Vol.13 (1), p.1222-1222, Article 1222

2023

Volltextzugriff (PDF)

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

The Journal of infectious diseases, 2016-02, Vol.213 (3), p.411-422

2016

Volltextzugriff (PDF)

Per‐ and polyfluoroalkyl substances and their alternatives in paper food packaging

Comprehensive reviews in food science and food safety, 2021-05, Vol.20 (3), p.2596-2625

2021

Volltextzugriff (PDF)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Nature communications, 2021-01, Vol.12 (1), p.372-372, Article 372

2021

Volltextzugriff (PDF)

Solution blow spinning: A new method to produce micro- and nanofibers from polymer solutions

Journal of applied polymer science, 2009-08, Vol.113 (4), p.2322-2330

2009

Volltextzugriff (PDF)

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

PloS one, 2012-11, Vol.7 (11), p.e50852

2012

Volltextzugriff (PDF)

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Vaccine, 2014-05, Vol.32 (26), p.3169-3174

2014

Volltextzugriff (PDF)

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

Vaccine, 2017-03, Vol.35 (12), p.1586-1589

2017

Volltextzugriff (PDF)

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age

Vaccine, 2017-06, Vol.35 (30), p.3749-3759

2017

Volltextzugriff (PDF)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses

The Journal of clinical investigation, 2022-10, Vol.132 (19)

2022

Volltextzugriff (PDF)

Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants

The Journal of infectious diseases, 2019-10, Vol.220 (11), p.1802-1815

2019

Volltextzugriff (PDF)

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

The Lancet infectious diseases, 2022-11, Vol.22 (11), p.1565-1576

2022

Volltextzugriff (PDF)

Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial

The Lancet infectious diseases, 2022-01, Vol.22 (1), p.73-84

2022

Volltextzugriff (PDF)

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

Vaccine, 2013-01, Vol.31 (3), p.524-532

2013

Volltextzugriff (PDF)

Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection

Vaccine, 2019-09, Vol.37 (41), p.6112-6124

2019

Volltextzugriff (PDF)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

The New England journal of medicine, 2023-03, Vol.388 (9), p.857-859

2023

Volltextzugriff (PDF)

1 – 25 von 1.517

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.331)
Mit Volltextzugriff
(1.279)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(955)
Life Sciences & Biomedicine
(737)
Humans
(445)
Female
(253)
Male
(252)
Biological And Medical Sciences
(237)
Animals
(220)
Physical Sciences
(149)
Adult
(139)
Medical Sciences
(115)
Aged
(108)
Middle Aged
(99)
Chemistry
(87)
Fundamental And Applied Biological Sciences. Psychology
(84)
Adolescent
(70)
Technology
(65)
Cardiovascular System & Cardiology
(62)
Aged, 80 And Over
(54)
Immunology
(52)
Mice
(52)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age

Per‐ and polyfluoroalkyl substances and their alternatives in paper food packaging

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Solution blow spinning: A new method to produce micro- and nanofibers from polymer solutions

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses

Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

Suchergebnisse filtern